

Vidutolimod

Cat. No.:	HY-148511
CAS No.:	147063-80-7
Molecular Weight:	9612.23
Sequence:	DNA, d(G-G-G-G-G-G-G-G-G-G-G-A-C-G-A-T-C-G-T-C-G-G-G-G-G-G-G-G-G)
Target:	Toll-like Receptor (TLR)
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Vidutolimod

BIOLOGICAL ACTIVITY

Description	Vidutolimod (CMP-001) is a CpG-A oligodeoxynucleotide. Vidutolimod is a Toll-like receptor 9 (TLR9) agonist, which activates plasmacytoid dendritic cells (pDCs) and triggers interferon alpha (IFN α) release, leading to a cascade of anti-tumor immune effects.
IC ₅₀ & Target	TLR9

REFERENCES

- [1]. Ribas A, Medina T, Kirkwood JM, et al. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. *Cancer Discov.* 2021;11(12):2998-3007.
- [2]. Sabree SA, Voigt AP, Blackwell SE, et al. Direct and indirect immune effects of CMP-001, a virus-like particle containing a TLR9 agonist. *J Immunother Cancer.* 2021;9(6):e002484.
- [3]. Cheng Y, Lemke-Miltner CD, Wongpattaraworakul W, et al. In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy. *J Immunother Cancer.* 2020;8(2):e000940.
- [4]. Negrao MV, Papadimitrakopoulou VA, Price AC, et al. Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC. *JTO Clin Res Rep.* 2022;4(3):100423. Published 2022 Oct 26.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA